NEUROMARK Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 70

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $29M

  • Investors
  • 11

NEUROMARK General Information

Description

Developer of a non-surgical intervention device designed to treat chronic rhinitis safely. The company specializes in minimally invasive hand-held radio-frequency devices that are introduced through the nostrils into the nasal cavity under direct endoscopic visualization where it deploys a microelectrode array that delivers targeted energy to interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade, enabling surgeons to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 150 Grossman Drive
  • Suite 203
  • Braintree, MA 02184
  • United States
+1 (800)
Primary Industry
Therapeutic Devices
Vertical(s)
Corporate Office
  • 150 Grossman Drive
  • Suite 203
  • Braintree, MA 02184
  • United States
+1 (800)

NEUROMARK Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NEUROMARK Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Debt - General 09-Sep-2026 $29M Completed Generating Revenue
9. Later Stage VC (Series C) 17-Feb-2026 Completed Generating Revenue
8. Later Stage VC 18-Dec-2024 Completed Generating Revenue
7. Later Stage VC 07-Jun-2022 Completed Generating Revenue
6. Accelerator/Incubator 30-May-2021 Completed Generating Revenue
5. Later Stage VC (Series B) 20-Jan-2021 Completed Generating Revenue
4. Later Stage VC (Series B) 07-May-2020 Completed Generating Revenue
3. Grant 10-Dec-2018 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Jul-2018 $10.8M $10.8M Completed Generating Revenue
1. University Spin-Out 01-Jan-2014 Completed Generating Revenue
To view NEUROMARK’s complete valuation and funding history, request access »

NEUROMARK Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A Preference
Series A Preference 123,547 $0.001089 $40.96 $40.96 1x $40.96 22.75%
To view NEUROMARK’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NEUROMARK Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a non-surgical intervention device designed to treat chronic rhinitis safely. The company specializes in mi
Therapeutic Devices
Braintree, MA
70 As of 2026

Shelton, CT
 

Brooklyn, OH
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NEUROMARK Competitors (8)

One of NEUROMARK’s 8 competitors is Spine Wave, a Venture Capital-Backed company based in Shelton, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spine Wave Venture Capital-Backed Shelton, CT
Naväge Private Equity-Backed Brooklyn, OH
Amplitude Surgical Formerly PE-Backed Valence, France
Boston Scientific Corporation Marlborough, MA
Merit Medical Systems Corporation South Jordan, UT
You’re viewing 5 of 8 competitors. Get the full list »

NEUROMARK Patents

NEUROMARK Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4773900-A1 Systems and methods for treating headache disorders Pending 05-Sep-2023
US-20250072955-A1 Systems and methods for treating headache disorders Pending 05-Sep-2023
WO-2025052173-A1 Systems and methods for treating headache disorders Inactive 05-Sep-2023
EP-4770551-A1 Device for therapeutic sino-nasal treatment Pending 28-Aug-2023
US-20250072951-A1 Device for therapeutic sino-nasal treatment Pending 28-Aug-2023 A61B18/14
To view NEUROMARK’s complete patent history, request access »

NEUROMARK Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NEUROMARK Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
MVM Partners Growth/Expansion Minority
Sofinnova Partners Venture Capital Minority
Claret Capital Partners Growth/Expansion Minority
MedTech Innovator Accelerator/Incubator Minority
EQT Life Sciences Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

NEUROMARK FAQs

  • When was NEUROMARK founded?

    NEUROMARK was founded in 2014.

  • Where is NEUROMARK headquartered?

    NEUROMARK is headquartered in Braintree, MA.

  • What is the size of NEUROMARK?

    NEUROMARK has 70 total employees.

  • What industry is NEUROMARK in?

    NEUROMARK’s primary industry is Therapeutic Devices.

  • Is NEUROMARK a private or public company?

    NEUROMARK is a Private company.

  • What is NEUROMARK’s current revenue?

    The current revenue for NEUROMARK is .

  • How much funding has NEUROMARK raised over time?

    NEUROMARK has raised $176M.

  • Who are NEUROMARK’s investors?

    MVM Partners, Sofinnova Partners, Claret Capital Partners, MedTech Innovator, and EQT Life Sciences are 5 of 11 investors who have invested in NEUROMARK.

  • Who are NEUROMARK’s competitors?

    Spine Wave, Naväge, Amplitude Surgical, Boston Scientific, and Merit Medical Systems are some of the 8 competitors of NEUROMARK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process